

1 **PADI4 minor haplotype as risk factor for excessive NET formation and** 2 **associated wound healing disorders in diabetes mellitus**

3 Sabrina Ehnert,^{1,*} Philipp Hemmann,¹ Christoph Ihle,¹ Caren Linnemann,¹ Jonas Mück,¹ Panagiota-
4 Georgia Anastasiou,^{1,2} Ralf Lobmann,² Gunnar Blumenstock,³ Stefan Pscherer^{1,4} Andreas Fritsche,⁵
5 Heiko Baumgartner,¹ Tina Histing,¹ Mika F. Rollmann,¹ Andreas K. Nussler¹

6 ¹ Siegfried Weller Research Institute; BG Unfallklinik Tübingen; Department of Trauma and
7 Reconstructive Surgery; University of Tübingen; Schnarrenbergstr. 95; D-72076 Tübingen; Germany;

8 ² Clinic for Endocrinology; Diabetology and Geriatric Medicine; Center for Internal Medicine; Klinikum
9 der Landeshauptstadt Stuttgart gKAöR, Katharinenhospital; Kriegsbergstrasse 60, D-70174
10 Stuttgart; Germany;

11 ³ Institute for Clinical Epidemiology and Applied Biometry; University of Tübingen; Silcherstr. 5; D-
12 72076 Tübingen; Germany;

13 ⁴ Department of Internal Medicine III, Sophien- and Hufeland-Hospital, Henry-van-de-Velde-Straße
14 2, D-99425 Weimar, Germany;

15 ⁵ Department of Internal Medicine, Division of Diabetology, Endocrinology, and Nephrology, Eberhard
16 Karls University Tübingen, Otfried-Müller-Straße 10, D-72076 Tübingen, Germany

17 **Corresponding author:** Sabrina Ehnert, Siegfried Weller Research Institute; BG Unfallklinik
18 Tübingen; Department of Trauma and Reconstructive Surgery; University of Tübingen;
19 Schnarrenbergstr. 95; D-72076 Tübingen; Germany; Tel: +49 (0)7071 606 1065; Email:
20 Sabrina.Ehnert@med.uni-tuebingen.de & Sabrina.Ehnert@gmail.com

21 **Conflict-of-interest statement:** The authors have declared that no conflict of interest exists. Parts
22 of the data presented were obtained during the doctoral thesis work of C.L., J.M., and P.-G.A.

23

24 **Abstract**


25 Diabetes mellitus (DM) complicates wound healing, partly due to excessive neutrophil extracellular
26 trap (NET) formation, a process regulated by the enzyme peptidyl-arginine deiminase 4 (PADI4).
27 Circulating NET markers can predict the healing outcome of chronic wounds, but may not allow
28 enough time for intervention as the accumulated NETs may have already damaged the tissue. In
29 search for an early detectable risk marker, this study aimed at relating PADI4 haplotype, to PADI4
30 expression, NET formation and clinical outcomes, *i.a.* infections, delayed wound and bone healing,
31 in 687 surgical patients (44.7% with DM). Pre-surgical PADI4 expression was 9.4-fold higher in
32 patients with DM, especially those with complicated wound healing. The study linked PADI4
33 haplotypes to NET formation and clinical outcomes, finding that neutrophils with the PADI4 minor
34 haplotype had higher PADI4 mRNA and protein levels and more rapidly produced a larger amount of
35 NETs than neutrophils with the PADI4 major haplotype. Patients with DM and the PADI4 minor
36 haplotype experienced the highest rates of delayed wound healing and infections. Our findings
37 suggest that the PADI4 haplotype influences neutrophil behavior and clinical outcomes, making it a
38 potential biomarker to screen patients with DM for their risk of developing wound healing
39 complications.

40
41 **Funding** This study received funding from the German Research Council (EH471/5-1) and the
42 Bundesministerium für Bildung und Forschung (13GW0661D). C.L. was supported by the
43 Studienstiftung des deutschen Volkes.

44 **Keywords** Diabetes, Wound Healing, Tissue Infection, Neutrophil Extracellular Traps, PADI4
45 haplotype

46

47 **Graphical Abstract**



48

49

50 **Introduction**

51 A constantly aging society and sedentary lifestyle made Diabetes mellitus (DM), especially DM type
52 2, the disease with the fastest growing incidence and prevalence worldwide. Based on reports from
53 the world health organization, DM is a major cause of blindness, kidney failure, heart attacks, or
54 stroke. Likewise, it is indisputable that DM affects the quality of bones and surrounding soft tissues,
55 increasing the risk of fractures and associated healing disorders, e.g., infections and/or delayed bone
56 and wound healing. Approximately every tenth develops a foot ulcer, diabetic foot syndrome, or
57 charcot-osteoarthropathy within the first 5 years of the disease. Of these roughly 20% will have
58 amputations of the lower limbs in the following 5 years, making DM the leading cause of non-
59 traumatic amputations worldwide (1). The resulting treatment costs exceed by far the costs for
60 treating the underlying disease (2), underlining the need to develop strategies to prevent these
61 diabetes-related complications.

62 For most complications, it is generally believed that patients with poor glycemic control and longer
63 disease duration are at highest risk. Considering diabetes-related complications of the kidneys, liver,
64 nerves and cardiovascular system, additional risk factors have been identified (3, 4). For diabetes-
65 associated complications following orthopedic or trauma surgery, information on risk factors, and
66 consequently treatment recommendations, are yet limited (5). It is assumed that certain anti-diabetic
67 drugs affect bone metabolism and thus influence the fracture risk (6). However, little is known about
68 risk factors for diabetes-associated complications in bone and wound healing.

69 In diabetic mice, a massive invasion of neutrophils into wounds was described. Within the wounds,
70 neutrophils were activated to form so-called neutrophil extracellular traps (NETs) (7), an unspecific
71 defense mechanism where neutrophils release their DNA together with citrullinated histones and anti-
72 microbial peptides in order to bind and neutralize pathogens (8). In wounds of diabetic mice, however,
73 an accumulation of NETs was observed, which impaired the wound healing (7), either indirectly by
74 stimulating local inflammation (9) or directly by acting as damage-associated molecular patterns
75 harming the surrounding tissue (10). These findings in mice have been reproduced in different
76 laboratories ever since (11-13). In humans, circulating NETs markers, e.g., neutrophil elastase

77 (ELANE), myeloperoxidase (MPO), citrullinated histones H3 (citH3), cell-free (cf) DNA, and
78 nucleosomes, were found to be increased in patients with DM, especially when having foot ulcers
79 (DFUs) - for review see (14). The levels of ELANE and citH3 were negatively associated with the
80 DFUs' spontaneous healing potential while relating to the amputation rate (12, 15). These findings
81 emphasize the important role of NET accumulation for impaired wound healing in patients with DM,
82 and thus provide opportunities for the development of novel treatment strategies. However, when
83 considering that the accumulated NETs may severely damage the surrounding tissue, measuring
84 circulating NET markers may not allow enough time to adjust the treatment in the clinical setting. In
85 order to gain time for treatment a biomarker that indicates the potential of neutrophils to form NETs
86 would be required.

87 Overexpression of peptidyl arginine deiminase 4 (PADI4) in neutrophils was identified to be
88 responsible for the overshooting NET formation in wounds of diabetic mice (7). PADI4 is known to
89 convert arginine residues to citrulline in proteins – in case of NETosis mainly in histones, inducing
90 nuclear decondensation (16). Even before NETs were first described, a dysregulated PADI4 activity,
91 was related to abnormal citrullination of auto-antibodies in patients with rheumatoid arthritis (RA) -
92 for review see (17). The link between PADI4 and onset and progression of RA was strengthened
93 when a genome wide association study identified a RA-associated PADI4 haplotype. This PADI4
94 functional haplotype consists of 3 single nucleotide polymorphisms (SNPs: rs11203366, rs11203367,
95 rs874881), all located on the first 2 exons of the PADI4 gene, resulting in 3 amino acid substitutions
96 in the N-terminal region of the PADI4 enzyme, affecting its structure (18). Special about this PADI4
97 haplotype is its high minor allele frequency, due to which approx. 22% of the worldwide population
98 are homozygous for the minor variant (mm; Figure 2A). Recently, other SNPs in the PADI4 gene
99 were proposed as potential risk loci in patients with rheumatoid arthritis, e.g., SNP rs2301888 (19),
100 rs2240336, and rs766449 (20), however, these SNPs do not belong to the described haplotype (R^2
101 < 0.37 , < 0.22 , < 0.59 , respectively) and failed statistical significance for an European population (19,
102 20), which is the expected majority in this study cohort.


103 Although increased PADI4 activity was associated with excessive NET formation in non-healing
104 diabetics wounds (14), no such relationships between the PADI4 haplotype and the healing potential
105 of diabetic wounds or DFUs was shown so far. Based on the mentioned literature it was hypothesized
106 that the PADI4 haplotype influences the neutrophils response to NET-stimuli and that this relates to
107 the clinical outcome of patients with DM undergoing trauma and/or orthopedic surgery. Therefore,
108 this study aimed to investigate the relationship between PADI4 haplotypes, pre-surgical neutrophilic
109 PADI4 expression, and clinical outcomes – specifically delayed wound healing, tissue infections, and
110 delayed bone healing – in patients (with and without diabetes) who underwent surgery at a level 1
111 trauma center. Additionally, the study sought to determine whether PADI4 haplotypes influence the
112 potential of neutrophils to form NETs.

113 **Results**

114 **Patients with DM have higher complication rates than patients without DM**

115 With the overall aim that the patients without DM fit those with DM regarding age, gender, and BMI,
116 725 patients qualified for our study. 38 patients were excluded from the study because they refused
117 to participate or blood sampling was not possible. Of the remaining 687 patients, 380 were assigned
118 for the control group (without DM) and 307 were assigned for the DM group, based on their medical
119 history, random blood glucose levels, and/or HbA1C values. The clinical data were independently
120 documented by two clinicians without knowing the laboratory data. The development of infections,
121 delayed wound healing, or delayed bone healing following primary interventions was counted as
122 complications. Revision surgeries were counted as complications when fitting into the above defined
123 categories – from these patients PADI4 haplotype was determined but not neutrophilic PADI4 gene
124 expression. Following this classification, the control group contained 245 patients (112 males and
125 133 females) without complications and 135 patients (90 males and 45 females) with complications.
126 Similarly, the DM group contained 112 patients (61 males and 51 females) without complications and
127 195 patients (129 males and 66 females) with complications. Interestingly, in the latter there was no

128 significant difference in HbA1C values of patients with ($7.8 \pm 1.8\%$ / $4.7 - 14.0$) and without
 129 complications ($9.0 \pm 3.2\%$ / $5.3 - 17.6$; [Figure 1A](#)). The VENN diagrams show frequent co-occurrence
 130 of 2 or 3 of the rated complications, especially in patients with DM ([Figure 1B](#)). The age distribution
 131 revealed that patients without DM (w/o: 59.4 ± 13.7 years / w/: 57.6 ± 14.9 years) were on average 6
 132 years younger than patients with DM (w/o: 63.5 ± 12.9 years / w/: 64.7 ± 11.4 years), regardless of
 133 the occurrence of a complication ([Figure 1C](#)). Similarly, the body mass index (BMI) was increased in
 134 patients with DM and complications (30.7 ± 6.1 kg/m²) as compared to patients without DM
 135 regardless of the occurrence of a complication (w/o: 28.3 ± 5.4 kg/m² / w/: 28.4 ± 5.8 kg/m²;
 136 [Figure 1D](#)). In diabetic mice increased neutrophilic PADI4 expression was associated with impaired
 137 wound healing (7). Therefore, PADI4 expression was determined in neutrophils, isolated prior to
 138 primary surgery. Basal PADI4 expression was significantly increased (1.9 ± 2.5 vs. 17.7 ± 45.6 ;
 139 $p < 0.0001$) in neutrophils from patients with DM when compared to matched patients without DM
 140 ([Figure 1E](#)).



141

142 **Figure 1: Overview on the patients' enrolment in this study.** (A) Patient selection process according to the STREGA
 143 guidelines, including patient assignment into the four study groups: patients without diabetes mellitus (Ctrl) and with
 144 diabetes mellitus (DM), each with (w/) and without (w/o) complications. Disturbed wound healing, delayed bone healing,

145 and post-surgical infections were counted as complications – when developed within 6 months after a primary intervention.
146 (B) The distribution of the complications is represented as VENN diagrams for patients with and without DM. For each
147 group (C) the patients' age and (D) the individual body mass index (BMI) were obtained. (E) in addition, pre-surgical (primary
148 intervention) PADI4 expression in circulating neutrophils was determined by quantitative real-time PCR in age and gender
149 matched patients (each N = 48). Data are displayed in scatter plots with median and inter-quartile range. Groups were
150 compared by (C&D) ordinary one-way ANOVA followed by Tukey's multiple comparison test or (E) Mann-Whitney test. A
151 $p < 0.05$ was considered statistically significant and is shown in the graphs.


152 **PADI4 genotype distribution is independent of the patients' sex, age, BMI, or prevalence for** 153 **diabetes mellitus**

154 All donors were characterized for PADI4 SNPs rs11203366, rs11203367, rs874881 by amplification-
155 refractory mutation system polymerase chain reaction (ARMS-PCR). The haplotype frequency within
156 the study cohort (51.2% A·C·C / 43.1% G·T·G / 5.7% other combinations) was comparable to the
157 reference data available from the 1000 genomes project. Based on these data, 194 patients (28.2%)
158 were identified to be homozygous for the major variant (MM) of PADI4, 116 patients (16.9%) were
159 identified to be homozygous for the minor variant (mm) of PADI4, and the remaining 377 patients
160 (54.9%) were identified to be heterozygous (Mm) of PADI4 (Figure 2A-C). Subgroup analyses
161 revealed, that the PADI4 genotype distribution was independent of the patients' age (Figure 2D), BMI
162 (Figure 2E), sex (Figure 2F), or prevalence for diabetes mellitus (Figure 2G).

163 **PADI4 expression is increased in neutrophils with the PADI4 minor haplotype**

164 A previous report stated that the PADI4 haplotype may affect the mRNA stability (21). Therefore, we
165 tested if the basal neutrophilic PADI4 expression levels related to the PADI4 haplotype in our
166 patients. Indeed, neutrophils from patients homozygous for the minor (mm) PADI4 haplotype showed
167 significantly higher PADI4 expression levels (4.4 ± 5.5) than neutrophils from patients heterozygous
168 (Mm: 2.0 ± 2.4) or homozygous for the major (MM: 1.1 ± 0.9) PADI4 haplotype (Figure 2H). Due to
169 the high linkage disequilibrium of the three SNPs, the same trend was observed when investigating
170 the effect of the individual SNPs on basal PADI4 expression levels. Of these, PADI4 SNP 335C>G
171 (rs874881) showed the strongest effect on PADI4 expression (Figure 3A).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




172

173 **Figure 2: Distribution of the PADI4 haplotype within the study cohort.** (A) SNPs within the coding region of the PADI4
 174 gene were retrieved from the Ensemble Genome Browser (<https://www.ensembl.org>). SNPs with a minor allele frequency
 175 > 0.01 were fed into the LDmatrix Tool from the LDlink app (<https://www.ldlink.nci.nih.gov>). Shown are the obtained D'
 176 (deviation of haplotype frequencies from expected values based on gene frequencies) and R² (coefficient of determination).
 177 The three SNPs with the highest D' and R², located within the PADI4 exons, and coding for an amino acid shift were used
 178 in this study. The haplotype frequency of these three PADI4 SNPs (rs11203366, rs11203367, rs874881) was determined
 179 using the LDhap Tool from the LDlink program. (B) The corresponding PADI4 haplotype frequency of the study cohort was
 180 determined by ARMS-PCR. Major and minor haplotype (homozygous) are marked as MM and mm, respectively. Mm:
 181 heterozygous. (C) The worldwide allele frequency of the three PADI4 SNPs was determined using the LDpop Tool from the
 182 LDlink app. (D) Basal PADI4 expression in circulating neutrophils (isolated prior to surgery) with different PADI4 haplotypes
 183 was determined by quantitative real-time PCR. Data are displayed as scatter plot and groups were compared by
 184 nonparametric Kruskal-Wallis test followed by Dunn's multiple comparison test. Haplotype distribution was determined
 185 based on the patients' (D) age, (E) body mass index (BMI), (F) sex, or (G) underlying disease (diabetes) and compared by
 186 chi-squared (χ^2) test. (H) For all experiments a $p < 0.05$ was considered significant.

187 Highest PADI4 expression in neutrophils from patients with DM developing complications

188 As increased neutrophilic PADI4 expression is supposed to affect wound healing (16), we related the
 189 PADI4 expression levels to the clinical outcome in our patients. PADI4 expression was overall higher
 190 in patients with DM when compared to patients without DM. While basal PADI4 expression levels did
 191 not significantly differ between patients without DM developing or not a complication, basal PADI4
 192 expression was increased on average by 2.1-fold, 3.7-fold, and 3.1-fold, respectively, in patients with
 193 DM developing an infection (Figure 3B), delayed wound healing (Figure 3C), or delayed bone healing

194 (Figure 3D). This also displayed in the corresponding receiver operating characteristic (ROC) curves,
 195 with areas under the curve (AUC) being significant for patients with DM (Infect: AUC = 0.6748,
 196 $p = 0.0381$ & DWH: AUC = 0.6949, $p = 0.0216$) but not for those without DM (Infect: AUC = 0.5209,
 197 $p = 0.7162$ & DWH: AUC = 0.5357, $p = 0.5603$) developing an infection or delayed wound healing
 198 (DWH; Figure 3E&F). For patients developing delayed bone healing (DBH) a similar trend (diabetics:
 199 AUC = 0.6533, $p = 0.1168$ & controls: AUC = 0.5318, $p = 0.6976$) was observed (Figure 3G).



200

201 **Figure 3: Association of the PADI4 haplotype with PADI4 expression and clinical outcome.** (A) PADI4 expression in
 202 circulating neutrophils (isolated prior to surgery) was determined by qRT-PCR and related to the three PADI4 SNPs
 203 rs11203366, rs11203367, and rs874881, determined by ARMS-PCR. Neutrophilic PADI4 expression was then compared
 204 between patients with and without Diabetes mellitus (DM), that did or didn't develop (B) infections, (C) delayed wound
 205 healing (DWH), and (D) delayed bone healing (DBH). Data are displayed in scatter plots and groups were compared by
 206 nonparametric Kruskal-Wallis test followed by Dunn's multiple comparison test. The PADI4 expression levels were used to
 207 generate receiver operating characteristic (ROC) curve for the development of (E) infections, (F) delayed wound healing,
 208 and (G) delayed bone healing in control and diabetic patients. PADI4 haplotype distribution based on the patients'
 209 underlying disease (controls vs. diabetics) and the clinical outcome, developing (H) infections, (I) delayed wound healing,
 210 and (J) delayed bone healing was compared by chi-squared (χ^2) test. For all experiments a $p < 0.05$ was considered
 211 significant.

212 **The highest rate of complications is seen in patients with DM and the PADI4 minor haplotype**

213 Based on the observed relation between neutrophilic PADI4 expression levels and both the PADI4

214 haplotype and the clinical outcome, the PADI4 haplotype was related to the clinical outcome of the

215 patients. Overall, the herein analyzed complications were documented more often in diabetics than
216 controls. In patients without DM, the rate of complications was comparable between patients
217 heterozygous or homozygous for the major or minor PADI4 haplotype. However, among the patients
218 with DM, those homozygous for the minor PADI4 haplotype developed significantly more infections
219 (mm: 60.7%) than those heterozygous (Mm: 36.5%) or those homozygous for the major (MM: 32.5%)
220 PADI4 haplotype (Figure 3H). The same holds for patients with DM and delayed wound healing – the
221 frequency was highest in those homozygous for the minor PADI4 haplotype (mm: 78.6%), followed
222 by those heterozygous (Mm: 38.8%) or homozygous for the major (MM: 36.3%) PADI4 haplotype
223 (Figure 3I). For patients with DM and delayed bone healing no such trend was observed (Figure 3J).
224 Single complication rates attributed to the PADI4 SNPs genotype or allele distribution in patients with
225 and without DM are summarized in Table 1. In line with the PADI4 haplotype distribution the minor
226 alleles of SNPs rs11203366 (A>G), rs11203367 (C>T), and rs874881 (C>G) strongly related to the
227 development of infections and delayed wound healing in patients with DM.

228 **PADI4 haplotype was associated with PADI4 protein levels and PADI4 activity**

229 As the PADI4 haplotype was related to the PADI4 gene expression levels, we tested their effect on
230 PADI4 protein levels in neutrophils isolated from healthy donors homozygous for the PADI4 major or
231 minor haplotype (Figure 4A). Neutrophils with the PADI4 minor haplotype had 2.0-fold higher basal
232 PADI4 levels than neutrophils with the PADI4 major haplotype. As a marker for PADI4 activity the
233 levels of citrullinated histone H3 (cit-H3) were quantified in these cells. Although, basal cit-H3 levels
234 were very low, their levels were 3.5-fold higher in neutrophils with the PADI4 minor haplotype when
235 compared to neutrophils with the PADI4 major haplotype (Figure 4B&C). As additional neutrophil
236 markers protein levels of neutrophil elastase (ELANE) and myeloperoxidase (MPO) were quantified.
237 While ELANE levels were not significantly affected by the PADI4 haplotype, basal MPO levels were
238 1.7-fold higher in neutrophils with the PADI4 major haplotype when compared to neutrophils with the
239 PADI4 minor haplotype (Figure 4D&E).

240

241 **Table 1.** Genotype and allele distribution within the study.


		All (N w/o : N w/)			Ctrl (N w/o : N w/)			DM (N w/o : N w/)		
		Infect	DWH	DBH	Infect	DWH	DBH	Infect	DWH	DBH
rs11203366										
Genotypes	<i>p-value</i>	0.0172	0.0005	0.0864	0.8894	0.7976	0.1919	0.0016	<0.0001	0.6415
	AA	131 : 52	128 : 55	70 : 30	78 : 27	78 : 27	45 : 9	53 : 25	50 : 28	25 : 21
	AG	277 : 114	270 : 121	115 : 84	168 : 51	165 : 54	68 : 29	109 : 63	105 : 67	47 : 55
	GG	65 : 48	57 : 56	33 : 26	43 : 14	45 : 12	15 : 6	22 : 34	12 : 44	18 : 20
Alleles	<i>p-value</i>	0.0370	0.0047	0.0635	0.8099	0.5767	0.1706	0.0033	<0.0001	0.5158
	A	539 : 218	526 : 231	255 : 144	324 : 105	321 : 108	158 : 47	215 : 113	205 : 123	97 : 97
	G	407 : 210	384 : 233	181 : 136	254 : 79	255 : 78	98 : 41	153 : 131	129 : 155	83 : 95
rs11203367										
Genotypes	<i>p-value</i>	0.0145	0.0004	0.1119	0.6937	0.6574	0.2789	0.0018	<0.0001	0.8392
	CC	139 : 57	135 : 61	72 : 32	86 : 31	85 : 32	49 : 11	53 : 26	50 : 29	23 : 21
	CT	268 : 108	262 : 114	112 : 81	159 : 46	157 : 48	64 : 27	109 : 62	105 : 66	48 : 54
	TT	66 : 49	58 : 57	34 : 27	44 : 15	46 : 13	15 : 6	22 : 34	12 : 44	19 : 21
Alleles	<i>p-value</i>	0.0432	0.0073	0.0683	0.7326	0.4086	0.2066	0.0045	<0.0001	0.6683
	C	546 : 222	532 : 236	256 : 145	331 : 108	327 : 112	162 : 49	215 : 114	205 : 124	94 : 96
	T	400 : 206	378 : 228	180 : 135	247 : 76	249 : 74	94 : 39	153 : 130	129 : 154	86 : 96
rs874881										
Genotypes	<i>p-value</i>	0.0468	0.0009	0.2292	0.5401	0.5879	0.3927	0.0018	<0.0001	0.8392
	CC	125 : 55	123 : 57	68 : 32	77 : 30	77 : 30	45 : 11	48 : 25	46 : 27	23 : 21
	CG	270 : 107	264 : 113	112 : 81	158 : 46	157 : 47	64 : 27	112 : 61	107 : 66	48 : 54
	GG	78 : 52	68 : 62	38 : 27	54 : 16	54 : 16	19 : 6	24 : 36	14 : 46	19 : 21
Alleles	<i>p-value</i>	0.1418	0.0123	0.1812	0.3889	0.3998	0.4616	0.0075	<0.0001	0.6683
	C	520 : 217	510 : 227	248 : 145	312 : 106	311 : 107	154 : 49	208 : 111	199 : 120	94 : 96
	G	426 : 211	400 : 237	188 : 135	266 : 78	265 : 79	102 : 39	160 : 133	135 : 158	86 : 96

242 *P-values* are given for the comparison of each MM vs. mm (genotypes) and M vs. m (alleles). Groups were compared by
 243 chi-squared (χ^2) test. DWH = delayed wound healing; DBH = delayed bone healing

244 **Increased basal NET formation in neutrophils homozygous for the PADI4 minor haplotype**

245 Neutrophils were isolated from healthy volunteers homozygous for the PADI4 major or minor
 246 haplotype and basal NET formation was detected SYTOX™ Green Assay. Time-laps fluorescent
 247 images showed more NETs formed in neutrophils with the PADI4 minor haplotype when compared
 248 to neutrophils with the PADI4 major haplotype (Figure 4F). Image analysis confirmed an increased
 249 cell size and higher amount of NETosed cells (Figure 4G) 145 min after isolation. Fluorescent signals
 250 quantified with an Omega plate reader were used for curve fitting. Basal NET formation occurred
 251 more rapidly (1.7-fold with Δ 76 min) in neutrophils homozygous for the PADI4 minor haplotype when
 252 compared to neutrophils homozygous for the PADI4 major haplotype. Further, neutrophils with the

253 PADI4 minor haplotype released 1.5-fold more DNA than neutrophils with the PADI4 major haplotype
 254 (Figure 4H).



255


256 **Figure 4: Basal NET formation in neutrophils with different PADI4 haplotype.** (A) Schematic overview of the
 257 experimental setup – created with icons from BioRender <https://www.biorender.com/>. Freshly isolated neutrophils from 16
 258 healthy donors homozygous for the major (MM: N = 8) or minor (mm: N = 8) PADI4 haplotype were examined for basal
 259 neutrophil activation. (B) Western blot images for PADI4 and citrullinated Histone H3 (citH3). (C) Western blot signals for
 260 PADI4 and citH3 were quantified by ImageJ software (each membrane with n = 3 exposure times). HPRT and β -actin were
 261 used as loading controls. (D) Dot blot images for neutrophil elastase (ELANE) and myeloperoxidase (MPO). (E) Dot blot
 262 signals for ELANE and MPO were quantified by ImageJ software (each membrane with n = 3 exposure times). Ponceau S
 263 staining was used as loading control. (F) Representative time-laps images of the performed SYTOXTM Green Assay.
 264 SYTOXTM Green signal intensities were visualized in ImageJ using “fire” pseudocolor. (G) Morphologic analyses (22)
 265 were performed to detect the average cell size and the number of NETosed cells after 145 min. (H) Curve fitting was done
 266 to determine the maximum NET release rate, represented by the strongest increase (slope) in fluorescence, and the time
 267 point of maximum NET release, represented by the inflection point of the slope. The total DNA released was determined
 268 by the area under the curve (AUC). Data are displayed in box plots with individual data points, median, and interquartile
 269 range. Data between two groups were compared by Mann-Whitney U-tests. A $p < 0.05$ was considered significant and is
 270 shown in the graphs.

271

272 **PADI4 minor haplotype sensitized neutrophils towards NETosis stimuli**

273 Isolated neutrophils from healthy volunteers homozygous for the PADI4 major or minor haplotype
274 were stimulated with 100 nM PMA or 4 μ M CI, in order to induce NETosis. Within 5 h following
275 stimulation different aspects of NET formation were documented (Figure 5A). Cell attachment and
276 activation were detected by bioimpedance measurement (Figure 5B). Directly after stimulation, the
277 group with the PADI4 minor haplotype showed a more rapid increase in cell index (cell attachment:
278 PMA: 2.0-fold and Δ 17 min; CI: 1.9-fold) than the group with the PADI4 major haplotype. The reaction
279 speed following CI stimulation was so quick that no difference between the two groups could be
280 detected. Later, when NET release predominated, the cell index decreased more rapidly (PMA: 2.8-
281 fold; CI: 1.7-fold) in the group with the PADI4 minor haplotype when compared to the group with the
282 PADI4 major haplotype (Figure 5C). As another aspect of NETosis, the DNA release was quantified
283 by SYTOXTM Green Assay (Figure 5D). Neutrophils homozygous for the PADI4 minor haplotype more
284 rapidly released (PMA: 1.3-fold with Δ 18 min; CI: 1.7-fold) a larger amount of DNA than neutrophils
285 homozygous for the PADI4 major haplotype (Figure 5E). To verify that necrotic cells did not interfere
286 with the SYTOXTM Green Assay, time-resolved fluorescent images were analyzed. The
287 representative compilation shows, that following stimulation neutrophils with the PADI4 minor
288 haplotype showed more NETosed cells (diffuse fluorescence) than neutrophils with the PADI4 major
289 haplotype. Noteworthy, stimulation with CI induced not only NETosis but also necrosis (condensed
290 fluorescence) in the neutrophils (Figure 5F). Automated image analyses confirmed this observation
291 – in PMA stimulated neutrophils, the average cells size and number of NETosed cells were
292 significantly higher in the group with the PADI4 minor haplotype (1.3-fold and 1.5-fold, respectively)
293 when compared to the group with the PADI4 major haplotype (Figure 5G).

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



294

295 **Figure 5: PMA- and CI-induced NET formation in neutrophils with different PADI4 haplotype.** (A) Schematic overview of
 296 the experimental setup – created with icons from BioRender <https://www.biorender.com/>. Neutrophils from 16 healthy
 297 donors homozygous for the major (MM) or minor (mm) PADI4 haplotype were examined for neutrophil activation upon
 298 stimulation with 100 nM Phorbol 12-myristate 13-acetate (PMA) or 4 μ M calcium ionophore A23187 (CI), respectively.
 299 Bioimpedance measurement [cell index], using the xCelligence RTCA eSight device, was used to identify early events in
 300 neutrophil activation. (A) Curve fitting for the average cell index measured (N = 8, N = 4 per group). (B) The maximum cell
 301 attachment rate was determined by the strongest increase (slope) in cell index. (C) The peak cell index represents the time
 302 point when NET release starts to superpose neutrophil attachment. (D) The maximum NET release rate is presented by
 303 the strongest decrease (slope) in cell index. In the same cells NET formation / DNA release was quantified by SYTOXTM
 304 Green Assay. (E) Curve fitting for the measured fluorescent intensities (N = 8, N = 3 per group). (F) The maximum NET
 305 release rate was determined by the strongest increase (slope) in fluorescence. (G) The time point of maximum NET release
 306 is represented by the inflection point of the slope. (H) The total DNA released was determined by the area under the curve
 307 (AUC). Using the xCelligence RTCA eSight device allowed online detection of fluorescent images from the SYTOXTM Green
 308 Assay. (I) Representative time-laps images of the performed SYTOXTM Green Assay with fluorescent intensities visualized
 309 in ImageJ using “fire” pseudocolor. Morphologic analyses (22) were performed to detect (J) the average cell size and (K)
 310 the number of NETosed cells after 145 min. Data are displayed in box plots with individual data points, median, and
 311 interquartile range. Data between two groups were compared by Mann-Whitney U-tests. A $p < 0.05$ was considered
 312 significant and is shown in the graphs.

313 Discussion

314 This study is the first to establish a link between the human PADI4 haplotype (SNPs: rs11203366,
315 rs11203367, rs874881) and wound healing complications in patients with DM undergoing orthopedic
316 and trauma surgery. Furthermore, this functional PADI4 haplotype was linked to neutrophilic PADI4
317 expression and influenced the neutrophils' ability to form NETs.

318 Tissue trauma, such as a wound or fracture, leads to release of mitochondrial DNA, which then
319 stimulates neutrophils to form NETs at the site of injury (23). Under normal conditions, this is thought
320 to prevent pathogens from colonizing the wound or entering the bloodstream to develop a sepsis.
321 Under diabetic conditions, however, NET accumulation was observed in the wounds, which impaired
322 the healing process (7). The resulting increase in circulating NET markers remains even after chronic
323 DFU have developed, and may predict the healing outcome (12, 15). In our patients, however, the
324 development of chronic wounds should be prevented. Considering that the accumulated NETs cause
325 damage to the tissue, measuring the amount of NETs formed may not be a suitable approach as it
326 leaves little window of opportunity to adjust treatment. In the diabetic mouse model neutrophilic
327 overexpression of PADI4 was identified as the key inducer for the excessive NET formation (7). In
328 line with this, pre-surgical neutrophilic PADI4 levels were significantly increased in our trauma
329 patients with DM, especially in those who later experienced delayed wound healing and/or developed
330 a wound infection. *In vitro*, forced overexpression of PADI4 was reported to induce histone
331 hypercitrullination leading to heterochromatin decondensation and chromatin unfolding (24), as well
332 as oxidative burst (25), which in case of neutrophils sensitizes the cells for NET stimuli and may even
333 induce spontaneous NET formation. This may explain, why in our experiments both basal and PMA-
334 induced NET formation was increased in neutrophils with increased PADI4 expression.

335 In our patients, pre-surgical PADI4 expression associated not only with the clinical outcome, but also
336 with the investigated PADI4 haplotype – with highest PADI4 expression observed in neutrophils
337 coding for the G T G alleles (minor variant). This is partly in contrast to patients with septic shock, in
338 whom increased PADI4 levels were positively associated to mortality but not with PADI4 SNP
339 rs11203366 (26), however, this might be due to the small sample size in the mortality group (N = 41).

340 A study characterizing the PADI4 protein structure proposed, that the base changes in our
341 investigated PADI4 haplotype may alter the PADI4 mRNA stability with prolonged mRNA stability for
342 the minor variant (21). This is supporting our findings, that neutrophils with the PADI4 minor haplotype
343 had higher PADI4 mRNA and protein levels. This in turn related with a basal increase in citH3,
344 suggesting that the PADI4 minor haplotype sensitizes neutrophils to release NETs. Indeed, PMA- or
345 CI-induced NET formation was faster and stronger in neutrophils with the PADI4 minor haplotype
346 than in neutrophils with the PADI4 major haplotype.

347 In line with the premise that excessive NET formation in wound tissue is associated with disturbed
348 wound healing in patients with DM, highest PADI4 expression and higher frequency of PADI4 minor
349 haplotype was found in neutrophils of patients who later developed a wound healing disorder.
350 Interestingly, the increased complication rate associated with the PADI4 minor haplotype could only
351 be shown in patients with DM, suggesting that DM provides additional NET stimuli. It was proposed
352 that increased glucose levels sensitize neutrophils to form NETs (27), more specifically, that
353 exogenous glucose and glycolysis promotes the actual NET release but not the initial chromatin
354 decondensation (28). Another study proposed that hyperglycemia supports just the latter by nuclear
355 accumulation of acetyl-CoA, which acts as substrate for histone acetyltransferases (29). Yet another
356 study suggested that not the glucose itself, but increased homocysteine levels in DM are the actual
357 trigger for NET formation (30). It is questionable if both factors can be discussed independently, as
358 homocysteine levels are positively associated with insulin resistance, dyslipidemia, and poor glucose
359 control (31). Both have in common that they induce cellular stress, which increases intracellular
360 calcium levels, a process involving gasdermine E (32, 33). The increase in intracellular calcium may
361 than act as a co-factor for the PADI4 enzyme (34), but also independently stimulate NET formation
362 as observed for stimulation with calcium-ionophore (35).

363 Hyperglycemia is well recognized as a normal metabolic stress response. Therefore, it should be
364 considered that our study cohort consists of trauma patients. In such patients' blood glucose control
365 is aggravated by the stress induced by a trauma and following surgery, resulting in frequent
366 hyperglycemic episodes (36). The resulting increase in basal PADI4 expression might explain, why

367 NET markers are stronger increased in patients with DM increased following trauma, but also offers
368 the opportunity for an intensified blood glucose control upon hospital admission. First hints are
369 provided from studies with critically-ill patients ($\Sigma N > 7,000$) in the intensive care unit (ICU) (37, 38).
370 In these patients, strict blood glucose control by intensified insulin treatment (IIT) reduced morbidity
371 and mortality, with the consequence of faster weaning of the mechanical ventilation, discharge from
372 the ICU and hospital. However, a subgroup analysis showed that only trauma patients and patients
373 receiving corticosteroid therapy may have an advantage in survival upon IIT (40). Furthermore, strict
374 glycemic control was shown to be significantly reduced (50-60%) the incidence of nosocomial
375 infections in surgical ICU patients (39).

376 Our data clearly link the PADI4 haplotype with the neutrophilic PADI4 expression in humans, which
377 in turn sensitizes the cells to form NETs. Therefore, genotyping for the PADI4 haplotype might
378 become a relevant screening tool in the future, not only to identify patients with DM at increased risk
379 of developing wound healing disorders but also for other pathologies, e.g., RA, sepsis, deep vein
380 thrombosis, multiple sclerosis, etc., where excessive NET formation and more precisely dysregulated
381 PADI4 activity has been shown to aggravate disease progression (16). This is of special importance
382 as such a haplotype screening can be done at the initial diagnosis of the disease, which allows for
383 early intervention. Considering the pathologic role of excessive NET formation could identify novel
384 therapeutic options for such diseases, e.g., enzymatic digestion of he formed NETs (7) or ir-
385 /reversible PADI4 inhibitors, e.g., GSK199, GSK484, TDCA, TDFA, JBI-589, F- or Cl-amidine (34,
386 41). However, treatment strategies should involve suppression of excessive NET formation not total
387 depletion of NETs, as this might increase the risk for infections and sepsis (42, 43).

388 **Conclusion**

389 In summary, we here provide first evidence that the PADI4 haplotype sensitizes neutrophils toward
390 NET formation and may serve as a predictive marker for wound healing disorders in patients with
391 DM following orthopedic or trauma surgery. Early genotyping of the PADI4 haplotype could help

392 identify patients with DM at higher risk for wound healing complications upon hospital admission,
393 enabling closer monitoring and/or personalized treatment to prevent complications.

394 **Methods**

395 **Study cohort and sampling**

396 Between September 2018 and February 2022, 687 patients were included in the study by giving their
397 written informed consent (666/2018BO2). During recruitment there was no discrimination by sex,
398 resulting in a sex distribution of 57.1% males (N = 392) and 42.9% females (N = 295). From each
399 individual, swabs of the mucous membrane or EDTA-venous blood were collected. Information about
400 the clinical outcome was independently collected by two physicians in a blinded manner. Disturbed
401 wound healing, delayed bone healing, and post-surgical infections were rated as complications, both
402 as result of a surgery or as cause for a revision surgery. Noteworthy, bone healing was not considered
403 in patients receiving a total joint arthroplasty. Clinical data were merged with the laboratory data only
404 when data acquisition was finished and verified by a second investigator.

405 **Isolation of neutrophils**

406 Neutrophils were isolated from EDTA-venous blood by density gradient centrifugation, as described
407 in (44). Isolated neutrophils were quantified by Trypan Blue exclusion method, then diluted to obtain
408 a density of 1 Mio neutrophils/mL (concentrated cell suspension).

409 **qRT-PCR**

410 Total mRNA from freshly isolated neutrophils was isolated by phenol-chloroform extraction and
411 photometrically quantified. Total mRNA was converted into cDNA using the first-strand cDNA
412 synthesis kit (ThermoFisher Scientific, Sindelfingen, GER). Quantitative RT-PCRs were performed
413 using the Green Master Mix (2X) High Rox (Biozym, Hessisch Oldendorf, GER) and the
414 StepOnePlus™ qPCR cycler. Specificity of the qPCR reactions was checked by melting curve
415 analyses. Relative PADI4 expression levels were calculated using the $\Delta\Delta C_T$ method, normalized to

416 *EF1α* and *RPL13a*, which proved to be most stable (GeNorm, NormFinder, Best Keeper,
417 comparative ΔC_t method) between individuals (45). PCR conditions are summarized in Table 2.

418 **Table 2.** Detailed information on primers (designed with primer blast) and the corresponding optimized qPCR conditions.

Target	GenID	Primer	efficiency	Amplicon	T _A
EF1α	NM_001402.5	For-CCCCGACACAGTAGCATTG	1.90	98 bp	56°C
		Rev-TGACTTTCCATCCCTTGAACC			
RPL13a	NM_012423.3	For-AAGTACCAGGCAGTGACAG	2.24	100 bp	56°C
		Rev-CCTGTTTCCGTAGCCTCATG			
PADI4	NM_012387.2	For-AGAGGTGACCCTGACGATGA	2.09	310 bp	56°C
		Rev-CAGGTCTTCGCTGTCAAGCA			

419 Amplification Refractory Mutation System (ARMS) PCR

420 DNA was isolated from residual leukocytes obtained from neutrophil isolation or swabs of the mucous
421 membrane, as described in (46). SNPs were characterized by ARMS-PCR (46), using 3 μ L of DNA
422 (50-100 ng/ μ L), a mix of 4 primers (Table 3), and the Red HS Taq (2X) Master Mix (Biozym). The
423 amplified DNA was separated by electrophoresis using a 2% agarose gel and visualized with
424 ethidium bromide.

425 **Table 3.** Primer sequences and ARMS-PCR conditions

SNP	primer	primer sequence (5' - 3')	amplicons		T _a
			flanking	allele specific	
rs11203366	IFP	AGGGGTGGTCGTGGATATTGCCCCCA	-	} 179 bp G-allele (m)	64°C
	ORP	AGCTCTTCCACAGGGCAAGAGGCTCTGC	} 382 bp		
	OFP	AGGAGAAATGCTGGGAGAGCCATGGCT		} 258 bp A-allele (M)	
	IRP	CCTGTGGATTTCTTCTTGGCTGGAGGTCC	-		
rs11203367	IFP	GGGTAGAGGTGACCCTGACGATGAACGC	-	} 168 bp T-allele (m)	68°C
	ORP	TGACCTCCATGAACCCCTGGTAGCCGTA	} 364 bp		
	OFP	GAGGACTGCACGTCCTCAGCATCAACG		} 250 bp C-allele (M)	
	IRP	CTGGTCGCCTGTGCTACCACTGGACA	-		
rs874881	IFP	CAAAGCTCTACTCTACCTCACGGG	-	} 183 bp G-allele (m)	62°C
	ORP	ACTCCCAGATGTCTGACTGGCT	} 387 bp		
	OFP	GCTTCCCTCCATTCCCATC		} 248 bp C-allele (M)	
	IRP	TGTTGTCACCTACCCAGCG	-		

426 Primers were designed using a program developed by Ye (<http://primer1.soton.ac.uk/primer1.html>) (47) and synthesized
427 by Eurofins Genomics (Ebersberg, Germany). IFP: inner forward primer, ORP: outer reverse primer, OFP: outer forward
428 primer, IRP: inner reverse primer

429 **Western blot and dot blot**

430 Neutrophils were lysed with ice-cold RIPA buffer with protease- and phosphatase inhibitors. For
431 Western blot 35 µg total protein was separated by SDS-PAGE and transferred to nitrocellulose
432 membranes. For dot blot 35 µg total protein was directly applied to nitrocellulose membranes under
433 vacuum using a dot blotter (Carl Roth, Karlsruhe, GER). Protein transfer to membranes was
434 confirmed by Ponceau S staining. Unspecific binding sites were blocked with 5% BSA for 1 h. After
435 overnight incubation with primary antibodies at +4°C (PADI4: sc-365369, HPRT: sc-376938, ELANE:
436 sc-55548, MPO: sc-52707 - SantaCruz Biotechnology, Heidelberg, GER); Cit-H3: ab5103 (abcam,
437 Cambridge, GBR); β-Actin: #4970 (Cell Signaling Technology, Danver, MA, USA)), membranes were
438 incubated with the corresponding peroxidase-labeled secondary antibodies for 2 h. Enhanced
439 chemiluminescence solution was added and the resulting signals were detected with a CCD camera
440 and quantified with ImageJ.

441 **Stimulation of neutrophils**

442 For all functional assays, neutrophils were stimulated with PMA (Phorbol 12-myristate 13-acetate) or
443 calcium ionophore A23187 (CI). Solutions were prepared as 1.25-fold of the final concentration to
444 allow measurement of blank (80 µL) and thereafter addition of concentrated cell suspension (20 µL)
445 to receive a final concentration of $2 \cdot 10^5$ neutrophils/mL (44).

446 **SYTOX™ Green Assay**

447 1.25 µM SYTOX™ Green was added to the stimulation solutions before the addition of neutrophils.
448 Cells were lysed with 1% Triton-X-100 (Carl Roth, Karlsruhe, Germany) for normalization and better
449 comparability of donors. Fluorescence ($\lambda_{ex}=485$ nm & $\lambda_{em}=520$ nm) was measured every 30 min with
450 the Omega Plate Reader (BMG Lab-tech) at 37°C and 5% CO₂. Curve fitting of the resulting XY
451 diagrams with GraphPad Prism included; (1) the maximum slope, which equals the maximum NET
452 release rate; (2) the inflection point of the slope, which defines the time till maximum NET release;
453 and (3) the area under the curve (AUC), which represents the total DNA released (44).

454

455 **Bioimpedance measurements and real-time fluorescent imaging**

456 The xCelligence RTCA eSight device (Omni Life Sciences), placed in an incubator at 37°C with 5%
457 CO₂ and humidified atmosphere, was used to measure bioimpedance [cell index] (44). Neutrophils
458 were stimulated in xCelligence measurement plates containing SYTOX™ Green for real-time
459 fluorescent imaging. After blank measurements, neutrophils were added and cell index was
460 measured at least every 15 min for a period of 6 h. Fluorescence pictures were captured at least
461 every 30 min. Curve fitting of the exported normalized data with GraphPad Prism included; (1) the
462 maximum positive slope, which equals the maximum cell attachment rate; (2) the peak time after
463 stimulation, which represents the time point when cell attachment and NET release are balanced;
464 and (3) the minimum negative slope, which represents the maximum NET release rate.

465 Real-time fluorescent images were exported as single tiff images and compiled in ImageJ: SYTOX™
466 Green signal intensities were visualized in “fire” pseudocolor. Images of the 145 min time point (one
467 image per well of the GFP channel) were subjected to automatic counting (particles >1,000 pixel²),
468 using an auto local threshold (Bernsen, radius 30) and watershed separation on the respective binary
469 images.

470 **Statistics**

471 Patient data are displayed in violin plots, visually confirming a Gaussian distribution (skewness and
472 kurtosis between -1 and 1). Data comparison was done by ordinary one-way ANOVA followed by
473 Tukey’s multiple comparison test. Complication rates in the different groups were compared by chi-
474 squared (χ^2) test. *In vitro* experiments were performed with neutrophils from 8 donors per group
475 (N = 8) with at least three technical replicates (n ≥ 3). Data are represented as box plots with
476 individual measurement points, median, and interquartile range. Given the smaller sample size,
477 Gaussian distribution cannot be assumed for the *in vitro* experiments, thus, data were compared by
478 Mann-Whitney U-tests. For all experiments a $p < 0.05$ was considered significant. GraphPad Prism
479 8.0.1 was used to perform statistical analysis and generate graphs.

480

481 **Study approval**

482 The study was approved by the ethics committee of the University Hospital Tübingen (ethical vote
483 666/2018BO2, approved 20.09.2018).

484 **Data availability:** All data supporting the findings of this study are available within the paper. The
485 anonymized dataset generated and analyzed during the current study are fully available without
486 restriction from the corresponding author.

487 **Author contributions:** S.E. – conceptualization of the study; funding acquisition; methodology and
488 investigations; formal analysis and validation of the laboratory data; data visualization; writing of the
489 manuscript draft. P.H. & C.I. – patient recruitment and retrieval of patient data; validation of the clinical
490 (trauma) data. C.L. & J.M. – methodology and investigations. P.-G.A. & R.L. – resources and patient
491 data; validation of the clinical (diabetes) data. G.B. – statistic counseling. S.P. & A.F. – recourses,
492 validation of the clinical (diabetes) data. H.B., M.F.R. & T.H. – resources and patient data. A.K.N. –
493 resources; supervision; validation of the laboratory data. All authors have reviewed and edited the
494 manuscript and agreed to its published version.

495 **References**

- 496 1. S. Pscherer, F. W. Dippel, S. Lauterbach, K. Kostev, Amputation rate and risk factors in type
497 2 patients with diabetic foot syndrome under real-life conditions in Germany. *Prim Care*
498 *Diabetes* **6**, 241-246 (2012).
- 499 2. I. Koster, L. von Ferber, P. Ihle, I. Schubert, H. Hauner, The cost burden of diabetes mellitus:
500 the evidence from Germany--the CoDiM study. *Diabetologia* **49**, 1498-1504 (2006).
- 501 3. O. P. Zaharia *et al.*, Risk of diabetes-associated diseases in subgroups of patients with
502 recent-onset diabetes: a 5-year follow-up study. *Lancet Diabetes Endocrinol* **7**, 684-694
503 (2019).

- 504 4. E. Ahlqvist *et al.*, Novel subgroups of adult-onset diabetes and their association with
505 outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol* **6**, 361-
506 369 (2018).
- 507 5. Y. Chen, Y. Zhou, J. Lin, S. Zhang, Challenges to Improve Bone Healing Under Diabetic
508 Conditions. *Front Endocrinol (Lausanne)* **13**, 861878 (2022).
- 509 6. Y. S. Zhang, Y. D. Zheng, Y. Yuan, S. C. Chen, B. C. Xie, Effects of Anti-Diabetic Drugs on
510 Fracture Risk: A Systematic Review and Network Meta-Analysis. *Front Endocrinol*
511 *(Lausanne)*, 735824 (2021).
- 512 7. S. L. Wong *et al.*, Diabetes primes neutrophils to undergo NETosis, which impairs wound
513 healing. *Nat Med* **21**, 815-819 (2015).
- 514 8. V. Brinkmann *et al.*, Neutrophil extracellular traps kill bacteria. *Science* **303**, 1532-1535
515 (2004).
- 516 9. S. Zhu *et al.*, The emerging roles of neutrophil extracellular traps in wound healing. *Cell Death*
517 *Dis* **12**, 984 (2021).
- 518 10. N. L. Denning, M. Aziz, S. D. Gurien, P. Wang, DAMPs and NETs in Sepsis. *Front Immunol*
519 **10**, 2536 (2019).
- 520 11. L. Menegazzo *et al.*, The antidiabetic drug metformin blunts NETosis in vitro and reduces
521 circulating NETosis biomarkers in vivo. *Acta Diabetol* **55**, 593-601 (2018).
- 522 12. G. P. Fadini *et al.*, NETosis Delays Diabetic Wound Healing in Mice and Humans. *Diabetes*
523 **65**, 1061-1071 (2016).
- 524 13. S. K. Das, Y. F. Yuan, M. Q. Li, Specific PKC beta11 inhibitor: one stone two birds in the
525 treatment of diabetic foot ulcers. *Biosci Rep* **38**, (2018).
- 526 14. R. Njeim *et al.*, NETosis contributes to the pathogenesis of diabetes and its complications. *J*
527 *Mol Endocrinol* **65**, R65-R76 (2020).
- 528 15. S. Yang *et al.*, Neutrophil Extracellular Traps Are Markers of Wound Healing Impairment in
529 Patients with Diabetic Foot Ulcers Treated in a Multidisciplinary Setting. *Adv Wound Care*
530 *(New Rochelle)* **9**, 16-27 (2020).

- 531 16. S. L. Wong, D. D. Wagner, Peptidylarginine deiminase 4: a nuclear button triggering
532 neutrophil extracellular traps in inflammatory diseases and aging. *FASEB J*, fj201800691R
533 (2018).
- 534 17. J. E. Jones, C. P. Causey, B. Knuckley, J. L. Slack-Noyes, P. R. Thompson, Protein arginine
535 deiminase 4 (PAD4): Current understanding and future therapeutic potential. *Curr Opin Drug*
536 *Discov Devel* **12**, 616-627 (2009).
- 537 18. A. Suzuki *et al.*, Functional haplotypes of PADI4, encoding citrullinating enzyme
538 peptidylarginine deiminase 4, are associated with rheumatoid arthritis. *Nat Genet* **34**, 395-
539 402 (2003).
- 540 19. Y. Okada *et al.*, Genetics of rheumatoid arthritis contributes to biology and drug discovery.
541 *Nature* **506**, 376-381 (2014).
- 542 20. S. Eyre *et al.*, High-density genetic mapping identifies new susceptibility loci for rheumatoid
543 arthritis. *Nat Genet* **44**, 1336-1340 (2012).
- 544 21. N. Horikoshi *et al.*, Structural and biochemical analyses of the human PAD4 variant encoded
545 by a functional haplotype gene. *Acta Crystallogr D Biol Crystallogr* **67**, 112-118 (2011).
- 546 22. V. Brinkmann, C. Goosmann, L. I. Kuhn, A. Zychlinsky, Automatic quantification of in vitro
547 NET formation. *Front Immunol* **3**, 413 (2012).
- 548 23. K. Itagaki *et al.*, Mitochondrial DNA released by trauma induces neutrophil extracellular traps.
549 *PLoS One* **10**, e0120549 (2015).
- 550 24. M. Leshner *et al.*, PAD4 mediated histone hypercitrullination induces heterochromatin
551 decondensation and chromatin unfolding to form neutrophil extracellular trap-like structures.
552 *Front Immunol* **3**, 307 (2012).
- 553 25. Y. Zhou *et al.*, Evidence for a direct link between PAD4-mediated citrullination and the
554 oxidative burst in human neutrophils. *Sci Rep* **8**, 15228 (2018).
- 555 26. N. A. Costa *et al.*, Peptidylarginine deiminase 4 concentration, but not PADI4 polymorphisms,
556 is associated with ICU mortality in septic shock patients. *J Cell Mol Med* **22**, 4732-4737
557 (2018).

- 558 27. L. Menegazzo *et al.*, NETosis is induced by high glucose and associated with type 2 diabetes.
559 *Acta Diabetol* **52**, 497-503 (2015).
- 560 28. O. Rodriguez-Espinosa, O. Rojas-Espinosa, M. M. Moreno-Altamirano, E. O. Lopez-Villegas,
561 F. J. Sanchez-Garcia, Metabolic requirements for neutrophil extracellular traps formation.
562 *Immunology* **145**, 213-224 (2015).
- 563 29. S. Shrestha *et al.*, Diabetes Primes Neutrophils for Neutrophil Extracellular Trap Formation
564 through Trained Immunity. *Research (Wash D C)* **7**, 0365 (2024).
- 565 30. M. B. Joshi *et al.*, Elevated homocysteine levels in type 2 diabetes induce constitutive
566 neutrophil extracellular traps. *Sci Rep* **6**, 36362 (2016).
- 567 31. X. Zhang *et al.*, Homocysteine inhibits pro-insulin receptor cleavage and causes insulin
568 resistance via protein cysteine-homocysteinylation. *Cell Rep* **37**, 109821 (2021).
- 569 32. S. Koushik *et al.*, PAD4: pathophysiology, current therapeutics and future perspective in
570 rheumatoid arthritis. *Expert Opin Ther Targets* **21**, 433-447 (2017).
- 571 33. D. N. Douda, M. A. Khan, H. Grasemann, N. Palaniyar, SK3 channel and mitochondrial ROS
572 mediate NADPH oxidase-independent NETosis induced by calcium influx. *Proc Natl Acad Sci*
573 *U S A* **112**, 2817-2822 (2015).
- 574 34. F. Ma *et al.*, Gasdermin E dictates inflammatory responses by controlling the mode of
575 neutrophil death. *Nat Commun* **15**, 386 (2024).
- 576 35. Y. P. Zhu *et al.*, NET formation is a default epigenetic program controlled by PAD4 in apoptotic
577 neutrophils. *Sci Adv* **9**, eadj1397 (2023).
- 578 36. P. L. Bosarge, J. D. Kerby, Stress-induced hyperglycemia: is it harmful following trauma? *Adv*
579 *Surg* **47**, 287-297 (2013).
- 580 37. G. Van den Berghe *et al.*, Intensive insulin therapy in the medical ICU. *N Engl J Med* **354**,
581 449-461 (2006).
- 582 38. G. van den Berghe *et al.*, Intensive insulin therapy in critically ill patients. *N Engl J Med* **345**,
583 1359-1367 (2001).

- 584 39. N. J. Grey, G. A. Perdrizet, Reduction of nosocomial infections in the surgical intensive-care
585 unit by strict glycemic control. *Endocr Pract* **10 Suppl 2**, 46-52 (2004).
- 586 40. N.-S. S. Investigators *et al.*, Intensive versus conventional glucose control in critically ill
587 patients. *N Engl J Med* **360**, 1283-1297 (2009).
- 588 41. C. Gajendran *et al.*, Alleviation of arthritis through prevention of neutrophil extracellular traps
589 by an orally available inhibitor of protein arginine deiminase 4. *Scientific reports* **13**, 3189
590 (2023).
- 591 42. W. Meng *et al.*, Depletion of neutrophil extracellular traps in vivo results in hypersusceptibility
592 to polymicrobial sepsis in mice. *Crit Care* **16**, R137 (2012).
- 593 43. A. P. Stewart *et al.*, Neutrophil extracellular traps protect the kidney from ascending infection
594 and are required for a positive leukocyte dipstick test. *Sci Transl Med* **16**, eadh5090 (2024).
- 595 44. C. Linnemann, S. Venturelli, F. Konrad, A. K. Nussler, S. Ehnert, Bio-Impedance
596 measurement allows displaying the early stages of Neutrophil Extracellular Traps. *EXCLI*
597 *Journal* **19**, 1481-1495 (2020).
- 598 45. R. H. Aspera-Werz *et al.*, Nicotine and Cotinine Induce Neutrophil Extracellular Trap
599 Formation-Potential Risk for Impaired Wound Healing in Smokers. *Antioxidants (Basel)* **11**,
600 (2022).
- 601 46. S. Ehnert *et al.*, One-Step ARMS-PCR for the Detection of SNPs-Using the Example of the
602 PADI4 Gene. *Methods Protoc* **2**, (2019).
- 603 47. S. Ye, S. Dhillon, X. Ke, A. R. Collins, I. N. Day, An efficient procedure for genotyping single
604 nucleotide polymorphisms. *Nucleic Acids Res* **29**, E88-88 (2001).